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Abstract: Diabetes mellitus (DM) is a major metabolic disorder currently affecting over 200 million people worldwide. 
Approximately 90% of all diabetic patients suffer from Type 2 diabetes mellitus (T2DM). The world's economy coughs 
out billions of dollars annually to diagnose, treat and manage patients with diabetes. It has been shown that the naturally 
occurring gut hormones incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-
1) can preserve the morphology and function of pancreatic beta cell. In addition, GIP and GLP-1 act on insulin receptors 
to facilitate insulin-receptor binding, resulting in optimal glucose metabolism. This review examines the medicinal chem-
istry and roles of incretins, specifically, GLP-1 and drugs which can mimic its actions and prevent its enzymatic degrada-
tion. The review discussed GLP-1 agonists such as exenatide, liraglutide, taspoglutide and albiglutide. The paper also 
identified and reviewed a number of inhibitors, which can block dipeptidyl peptidase 4 (DPP-4), the enzyme responsible 
for the rapid degradation of GLP-1. These DPP-4 inhibitors include sitagliptin, saxagliptin, vildagliptin and many others 
which are still in the experimental phase.  
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INTRODUCTION 
  Diabetes mellitus (DM) is a metabolic disease character-
ized by hyperglycemia [1]. DM is due to a reduction in the 
level or effectiveness of insulin. Insulin is produced in the 
pancreatic islets of Langerhans and induces glucose uptake 
into liver, muscle and fat cells [2]. Two distinct types of DM 
have been recognized, Type 1 and Type 2. Type 1 DM, also 
known previously as insulin-dependent or juvenile onset 
diabetes, is usually seen in children and young adults, and is 
caused by the immune-mediated destruction of pancreatic 
beta cells [3]. Type 2 (T2DM) previously referred to as non-
insulin-dependent diabetes mellitus (NIDDM) is the most 
common type of diabetes and is characterized by varying 
severities of insulin resistance [1, 2]. Factors that play a role 
in the pathogenesis of T2DM include, but not limited to re-
sistance of receptors to the insulin molecule, high glucose 
release by the liver, reduced insulin-mediated glucose uptake 
into muscle cells and adipocyte-related cytokines, and less 
than optimal pancreatic beta cell function. While the current 
T2DM drugs that enhance insulin release have been thera-
peutically beneficial, they are associated with several side 
effects including unpredictable hypoglycemia and body   
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weight gain. Thus, there is a need for more effective drugs, 
with fewer side effects, to treat T2DM [1-3]. 
  Currently, more than 200 million people worldwide have 
DM, of which 5-10% are Type 1 while the remaining 90-
95% suffer from T2DM [4, 5]. T2DM is caused mainly by a 
sedentary life style, obesity, hereditary and many other envi-
ronmental factors [1, 2]. The management of these patients 
possesses an enormous burden on the healthcare systems 
worldwide. It is thus of paramount importance, therefore that 
urgent steps be taken to reduce the cost of managing DM [6].  
  The pancreatic beta cell mass of a normal person can 
adapt to different insulin requirements when challenged with 
different glucose loads. However, the ability of pancreatic 
beta cell to release optimal and effective insulin may be 
compromised is diabetes. The inability of pancreatic beta 
cells to balance insulin resistance is a major problem in pa-
tients with impaired glucose tolerance or overt DM. This 
defect is due to a structural lesion in the insulin molecule or 
its receptors. It may also be due to the inability of the endo-
crine pancreas to maintain optimal beta cell mass capable of 
producing the required amount of effective insulin [5]. This 
concept has triggered the development of newer therapeutic 
strategies capable of preserving and/or regenerating a viable 
pancreatic beta cell mass. Regeneration, undoubtedly, is 
regulated by a constant interplay of beta cell growth (replica-
tion from mature beta cells and de novo formation from pre-Role of Incretins and DPP-4 Inhibitors in Diabetes  The Open Medicinal Chemistry Journal, 2011, Vol. 5    83 
cursor cells in pancreatic tissue) and beta cell death (mainly 
by apoptosis) [8]. Disruption of this interplay may lead to 
rapid and large changes in the viability of pancreatic beta 
cell mass. A new class of bioactive agents called incretins, 
originally developed to counter postprandial hyperglycae-
mia, have been observed to be capable of enhancing beta cell 
survival, thus contributing to the long-term, optimal regula-
tion of insulin secretion. The development of drugs that 
regulate pancreatic beta cell mass will be a strong tool in the 
management of patients with T2DM [9].  
  Long term T2DM put a lot of stress on pancreatic beta 
cells. The impact of high work load and hyperglycaemia-
induced oxidative stress lead, eventually, to pancreatic beta 
cell death. Some T2DM patient may thus convert to T1DM 
patients in severe cases. Any bioactive agent, including in-
cretins and DPP-4 inhibitors, that is capable of reducing hy-
perglycemia directly or indirectly can prevent pancreatic beta 
cell loss and facilitate its regeneration. 
THE THERAPEUTIC ROLE OF INCRETINS IN DIA-
BETES MELLITUS 
  It has long been shown that hormones of the gastrointes-
tinal system can modulate the secretory activities of the islets 
of Langerhans. Studies have shown that insulin release is 
much greater when glucose is ingested by mouth compared 
to when it is administered intravenously [10]. These bioac-
tive agents mediating the greater insulin secretion from pan-
creatic beta cells in response to oral glucose were referred to 
as incretins [11, 12].  
  The first set of biologically active incretins to be identi-
fied was the gut-derived hormone glucose-dependent insuli-
notropic polypeptide (GIP) [13-15]. GIP is also known as 
gastric inhibitory polypeptide.  Glucagon-like peptide-1 
(GLP-1) as shown in Fig. (1) was recognized to have a po-
tent insulinotropic activity, and collectively, GIP and GLP-1 
have been shown to account for as much as 50% of the insu-
lin released immediately after meal ingestion [15]. GIP and 
GLP-1 exert their physiological effects via the activation of 
their respective, almost ubiquitous trans-membrane G-
protein-coupled receptors (GPCR), which amount to about 
seven in number. These GLP specific GPCRs are found on a 
variety of tissues in addition to pancreatic beta cells, indicat-
ing that incretins have other biological roles beyond that 
involving the release of insulin into the blood stream [15, 
16]. GLP-1 also inhibits emptying of food from the stomach; 
thus increases satiety in general and, therefore, decreases 
food intake. It is also believed that GLP-1 influences learn-
ing and memory and has been implicated in the regulation of 
several cardiovascular functions [17-20]. A number of extra-
pancreatic effects, including the promotion of lipolysis in 
adipocytes and maintenance of bone mass have also been 
attributed to GIP by many investigators [16, 21, 22]. Al-
though these two incretins (GIP, GLP-1) promote beta cell 
survival with a concomitant increase in plasma insulin level, 
they have different effects on how glucagon is secreted. GIP 
stimulates glucagon release, while GLP-1 inhibits it [15, 23]. 
  GIP and GLP-1 are quickly deactivated by dipeptidyl 
peptidase-4 (DPP-4) [24]. DPP-4, found in many types of 
tissues, can cleave the active peptide at position 2 alanine 
(N-terminal) resulting in an inactive compound [25]. Previ-
ous reports have shown that DPP-4 is also found in the endo-
thelium of capillaries that drain the intestinal mucosa where 
GLP-1-secreting cells are situated [25, 26] indicating that 
most of the GLP-1 is inactivated almost immediately, fol-
lowing secretion. This immediate degradation of GLP-1 and 
GIP contributes to very short half-lives of less than 2 min 
and 5–7 min, respectively [24, 25, 27, 28]. This short half-
life limits the therapeutic potential of incretins. To overcome 
this problem, modifications of the amino acids at the N-
terminus of GLP-1 or GIP were done. The disadvantage of 
this phenomenon is that these modifications may result in 
insensitivity to the DPP-4 molecule, leading to unpredictable 
levels of biological effects [29]. 
SELECTED INCRETIN AGONISTS 
Exenatide 
  Exenatide is a synthetic form of exendin-4, a naturally 
occurring peptide consisting of 39-amino acids [24, 30] (Fig. 
1). It was originally isolated from the salivary fluid of the 
lizard  Heloderma suspectum (gila monster). It is a partial 
structural analogue of human GLP-1 and shares 53% amino 
acid sequence similarity with human GLP-1. It functions as 
an incretin-mimetic polypeptide, which binds to and stimu-
lates GLP-1 receptor located on plasma membranes. GLP-1 
receptor belongs to the class of ubiquitous, transmembrane 
receptors known as GPCR (G-protein couple receptors). In 
contrast to GLP-1 peptide, which contains the amino acid 
alanine at position 2, exenatide instead has glycine at posi-
tion 2, making it unrecognisable by DPP-4. This modifica-
tion allows exenatide to have much longer plasma half-life 
compared to GLP-1 [24, 31]. 
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  Exenatide has been shown to be able to help maintain 
beta cell mass and function by increasing the expression of 
beta-cell genes which promote islet-cell proliferation and 
neogenesis, and inhibit apoptosis in pancreatic islet cells [32-
36]. Exenatide has a short-term effect on pancreatic beta-cell 
responsiveness to glucose, leading to insulin release espe-
cially when the body is faced with acute hyperglycemia. In-
sulin secretion is thus reduced as blood glucose levels gradu-
ally decrease [31]. 
Liraglutide (a Fatty Acid Derivative of GLP-1) 
  Liraglutide is an analogue and fatty acid derivative of 
GLP-1. Its 16-carbon fatty acid chain is linked to Lys as 
shown in (Fig. 2). This association masks the cleavage point 
of liraglutide making it resistant to DPP-4 degradation [29], 
in a similar way as exenatide. Liraglutide, at therapeutic con-
centrations, lowers fasting and post-prandial plasma glucose 
in patients suffering from T2DM [37] and delays the outflow 
of food from the stomach [38]. It also produces a gradual 
increase in insulin release depending on the glucose load, via 
improvements in pancreatic beta cell viability (increases in 
cell mass coupled with inhibition of apoptosis). [39-41]. Like 
GLP-1, liraglutide suppresses glucagon in a glucose-
dependent manner, immediately after a meal is taken [38].  
Other Incretin Analogues and Agonists 
  The introduction of a long acting exenatide (manufac-
tured by Eli Lilly), capable of reducing HbA1c, fasting 
plasma glucose and body weight is currently undergoing 
clinical trials [42-44]. These promising results have led to 
the development of taspoglutide, a long-acting, once-a-week 
analogue of GLP-1 by Roche and its European Pharmaceuti-
cal Company, Ipsen. Initial studies have shown that this 
long-acting GLP-1 analogue induces a lower HbA1c and 
causes significant body weight loss [45]. Albiglutide (Glas-
gow SmithKline) is an albumin-fusion GLP-1 agonist [46], 
with a plasma half-life of 7 days and a T-max of 3–4 days 
[47, 48], can maintain therapeutic levels for a much longer 
time in the body. Albiglutide treatment causes reductions in 
24-h weighted mean glucose and postprandial concentrations 
with a relatively low risk of the patient being hypoglycemic 
[47]. It also stimulates GLP-1 receptor–dependent signalling 
pathways resulting in insulin release leading to reduction in 
blood glucose level [49]. (Fig. 2). 
Use of Recombinant Technology to Modify GLP-1 Action 
  The administration of rAd-GLP-1 (recombinant adenovi-
ral vector expressing GLP-1) to experimental diabetic mice 
resulted in remission of DM within a period of 10 days. In 
addition, normoglycaemia persisted until the end of the ex-
periment [50]. Gene transfer of the plasmid coding for the 
GLP-1/Fc peptide in db/db mice has shown that animals 
hosting the plasmid displayed a normalized glucose toler-
ance curve compared to control [51]. It does appear, there-
fore, that gene therapy can facilitate overexpression of GLP-
1 related peptides and could therefore have a potential thera-
peutic significance in the treatment of diabetes mellitus in 
the future. 
The Dipeptidyl-Peptidase 4 (DPP-4) as a Target Enzyme 
in the Treatment of Diabetes Mellitus 
  The half life of a functional GLP-1 molecule is less than 
2 min and that of GIP is approximately 7 min [52]. Thus 
indicating that without changing their molecular structure, 
these incretins cannot be used therapeutically because of 
rapid clearance from body systems. This complete and rapid 
clearance of incretin hormones is via DPP-4. Thus, inhibition 
of DPP-4 to prevent the fast decay of incretins appears to be 
a promising therapeutic goal in the treatment of diabetes 
[53]. 
  DPP-4 is a large, 766 amino acid membrane-associated, 
serine-type protease enzyme. For DPP-4 to be effective, a 
dipeptide must cleave off from the N-terminal [54]. The en-
zyme is widely detected in numerous tissues such as kidney, 
liver, intestine, spleen, lymphocytic organs, placenta, adrenal 
glands, and vascular endothelium. DPP-4 inhibitors exert 
their hypoglycaemic effect indirectly by improving the lon-
gevity, plasma concentration and action of incretins [55]. 
  DPP-4 inhibitors are orally active, small molecular 
weight drugs that can inhibit more than 90% of plasma DPP-
4 activity for over 24 h period [56]. These agents increase 
active incretin levels by preventing their rapid degradation. 
Thus, DPP-4 inhibitors are dependent on endogenous in-
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cretin secretion and could thus be effectively used early in 
T2DM, when pancreatic beta cell store of insulin is not com-
pletely exhausted [57]. 
  A major mechanism underlying the anti-diabetic effect of 
DPP-4 inhibitors is increased concentrations of biologically 
active GLP-1 and GIP, as has been shown after ingestion of 
a meal [58]. This DPP-4 inhibitor induced increase in the 
concentration of GLP and GIP persists during an entire 24 h 
period [59]. DPP-4 inhibitor administration also induces im-
proved pancreatic beta cell activity, as shown by improved 
insulin release [59, 60], and reduced inactive insulin-to-
active insulin ratio [61, 62]. DPP-4 inhibition also suppresses 
glucagon release [58, 59], which corresponds to reduction in 
hepatic glucose production. This is particularly important 
because a worsening diabetes is associated with an increase 
in the level of glucagon. Insulin sensitivity is improved re-
sulting in reduced plasma blood glucose levels after DPP-4 
inhibition [63-65].  
  Several DPP-4 inhibitors have been produced [66, 67], 
and they include vildagliptin (1) (LAF237) marketed as 
Galvus, by Novartis; sitagliptin (2) (MK-0431) sold as Janu-
via by Merck and saxagliptin (3) (BMS-477118, a product of 
Bristol-Myers Squibb, that competitively and reversibly in-
hibit the enzyme, DPP-4 [68-70]. These DPP-4 inhibitors are 
rapidly absorbed when given orally and the Cmax is observed 
within 1-2 h of administration. Bioavailability is said to be 
more than 80% after oral dosage.  
 Vildagliptin  (1) is hydrolyzed to an inactive compound 
excreted via the kidney into urine. However, approximately 
20% of vildagliptin (1) is disposed from our body un-
changed. In contrast, sitagliptin (2) is primarily excreted as is 
by the kidney and, therefore, renal insufficiency may in-
crease the circulating level of sitagliptin (2) [71] leading to 
abnormal plasma levels of the drug. An overdose of sita-
gliptin (2) may possibly lead to hypoglycaemia. The metabo-
lism of saxagliptin (3) occurs mainly in the liver. The active 
compound and unconverted saxagliptin (3) and other me-
tabolites are however, released via the kidney into urine. 
Hepatic insufficiency does not seem, therefore, to alter the 
pharmacokinetics of these compounds. Drug-drug interaction 
does not seem to be an issue with patients taking DPP-4 in-
hibitors [71]. (Table 1). 
Sitagliptin 
 Sitagliptin  (2) (MK-0431) is an oral preparation of a 
DPP-4 inhibitor [72]. It has been approved by the FDA as a 
single therapy for the treatment of diabetes but can be added 
to metformin or glitazone, when metformin plus diet regi-
men is not producing the required result [73, 74]. In Europe, 
a monotherapy with sitagliptin (2) is given either primarily 
for patients with a new onset of diabetes mellitus or because 
of ineffectiveness of other oral hypoglycaemic agents. Sev-
eral reports have suggested that sitagliptin (2) can be added 
to either metformin, or glitazone, a sulfonylurea, or in a tri-
ple combination with both metformin and a sulfonylurea, but 
not with a glinide [61, 75, 76]. A combination of sitagliptin 
(2) with metformin in particular has been reported to be 
beneficial for an optimal pancreatic beta cell function [77, 
78]. 
 Sitagliptin  (2) when given alone can induce large inhibi-
tion in DPP-4 activity of up to 96% at 2 h, and 80% at 24 h 
after administration [79]. A single oral course of sitagliptin 
(2) was reported to increase GLP-1 response to oral glucose 
tolerance test significantly, resulting in a large decrease in 
blood glucose level [79].  
  Administration of sitagliptin to streptozocin-induced dia-
betic rats, fed on high-fat diet caused large and significant 
increases in the number of pancreatic beta cells in the islets 
of Langerhans, resulting in improved beta cell mass and 
beta-cell-to-alpha-cell ratio. Sitagliptin (2) also reduced the 
plasma level of HbA1c, triglycerides and free fatty acids in 
rodent models of diabetes [80]. In patients suffering from 
T2DM, the administration of sitagliptin (2) increases the 
plasma levels of insulin and C-peptide with a concomitant 
reduction in the plasma level of glucagon [79], resulting in a 
well balanced glycemic control (Table 1). 
Vildagliptin  
 Vildagliptin  (1) (LAF237) marketed as Galvus® is the 
second DPP-4 inhibitor to be approved, in 2008, in the 
Europe Union for the management of diabetes mellitus. The 
molecular structures and pharmacokinetics of sitagliptin (2) 
and vildagliptin (1) are different. Sitagliptin (2) is a competi-
tive antagonist of DPP-4 while vildagliptin (1), as well as 
saxagliptin (3) are substrates for DPP-4, thereby inhibiting 
the target molecule. Vildagliptin (1) has a high affinity for 
DPP-4 [62, 81, 82]. This strong affinity enables vildaliptin 
(1) to induce large reductions in the plasma HbA1c level of 
patients with T2DM [83]. In addition, vildagliptin (1) in-
creases fasting and postprandial GLP-1 level, and induces 
pancreatic beta cell sensitivity to glucose and insulin. It also 
has the ability to significantly lower postprandial lipaemia. 
In contrast to many other DPP-4 inhibitors, vildagliptin (1) 
does not slow the outward flow of food from the stomach. 
Table 1.  Chemical Structures of Selected DPP-4 Inhibitors 
 Compound  Chemical  Structure 
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These therapeutic effects of vildagliptin (1) described above 
may help to improve glucose tolerance and achieve normo-
glycemia [84-86]. Other study showed that vildagliptin (1) 
can significantly increase insulin release [87] with a simulta-
neous reduction in glucagon levels especially in the post-
meal period [88, 89]. 
 Vildagliptin  (1) causes a reduction in glucagon/insulin 
ratio and a lower endogenous glucose production during both 
the postprandial and post-absorptive phases [87]. Clinical 
trials have shown that vildagliptin (1) induces significant 
improvements in glycemic control in T2MD patients as 
demonstrated by large reductions in the level of HbA1c 
when used alone or in combination with other hypoglycae-
mic agents such as metformin. Although vildagliptin (1) im-
proves pancreatic beta cell function in patients with T2DM it 
does not contribute to body weight gain [60]. The plasma 
concentration of proinsulin, a marker of abnormal beta cell 
function, is significantly reduced in patients treated with 
vildagliptin (1) [62]. Vildagliptin (1) can reduce lipolysis as 
well as postprandial hypertriglyceridemia [89] probably be-
cause of vildagliptin-induced higher plasma concentration of 
incretin, which has been reported to reduce intestinal absorp-
tion of triglyceride in animal studies [90]. (Table 1). 
Saxagliptin 
 Saxagliptin  (3) is a relatively new selective and reversi-
ble DPP-4 inhibitor, developed by Bristol-Myers Squibb and 
AstraZeneca for the treatment of diabetes mellitus. The 
phase 3 clinical trial of saxagliptin (3) has recently been 
completed [91]. Saxagliptin was approved by the FDA in 
July 31, 2009 and marketed under the tradename of 
Onglyza®. It is a highly potent DPP-4 inhibitor, about 10 
times more potent than either vildagliptin (1) or sitagliptin 
(2) [92]. The first clinical study shows that saxagliptin (3) 
can reduce the signs and symptoms of diabetes mellitus. It 
has the ability to reduce HbA1c level when given, once-
daily, to drug-naive patients [93, 94]. Saxagliptin (3) also 
induced large and significant reductions in fasting and post-
prandial blood glucose levels [93, 95]. 
  Some studies have examined the efficacy of saxagliptin 
(3) and other drugs in inadequately controlled patients with 
T2DM in terms of the degree of reductions in HbA1c. The 
administration of oral saxagliptin (3) at 2.5-10 mg, once-
daily, in combination with metformin provided significant 
reductions in HbA1c level when compared to placebo. Saxa-
gliptin (3) caused large reductions in blood glucose levels 
compared to placebo [96]. It has been reported that patients 
tolerate saxagliptin (3) well, as it does not cause significant 
hypoglycemia. The effect of saxagliptin (3) on body weight 
gain has not been widely assessed, but the limited data avail-
able in the literature suggest that it has little or no impact on 
body weight [91] (Table 1). 
Newer DPP-4 Inhibitors  
 Denagliptin  (4), produced by Glaxo Smith Kline, 
showed significant differences in its pharmacokinetics, side-
effects and clinical activity when compared to the currently 
available DPP-4 inhibitors such as vildagliptin and saxa-
gliptin. This may be due to the extra fluoride molecules that 
denagliptin (4) has. The clinical effects attributed to dena-
gliptin (4) have not been thoroughly documented [97]. De-
nagliptin is still very much in the experimental phase and 
awaits approval for use in clinical practice (Table 2). 
 Alogliptin (5) (SYR-322) developed by Takeda Pharma-
ceutical Company, Japan, is a quinazolinone-denominated 
DPP-4 antagonist. It has been reported that between 45% and 
88% of the total alogliptin ingested orally is available for 
biological action [98]. The few studies performed on the 
effect of alogliptin in diabetics have shown its ability to 
normalize glycemic levels [99]. (Table 2). 
 P32/98 (6) also called Isoleucine thiazolidide has been 
reported to increase pancreatic beta cell mass in animal mod-
els of diabetes [100] (Table 2). However, further reports are 
still needed to investigate its role in the management of dia-
betes mellitus and any possible side effects. 
Table 2.  Chemical Structures of Newer DPP-4 Inhibitors -1 
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  Linagliptin (BI 1356) ( 7) developed by Boehringer-
Ingelheim, was given the trade name of Tradjenta. BI 1356 
(7) is a xanthine derivative with a strong capacity to dissoci-
ate DPP-4 at a very low velocity. Initial investigations have 
shown that BI 1356 (7) attaches to its main target molecule 
at low plasma concentrations, making it an ideal drug. The in 
vivo duration of action of BI 1356 (7) is more prolonged 
when compared to other DPP-4 inhibitors, making it possible 
to be administered as a once-a-day anti-diabetic drug [101]. 
A once-a-day regimen will improve compliance in patients 
with a busy schedule. Although BI 1356 (7) increases basal 
GLP-1 level, it does not increase plasma insulin concentra-
tion in rats 24 h after its administration [102]. BI 1356 (7) 
has been shown to be able to produce more than 80% DPP-4 
inhibition at therapeutic dosage [102] (Table 2). 
 Dutogliptin  (PHX1149)  (8), manufactured by Phenomix 
Corporation, is an aqueous DPP-4 inhibitor. It is excreted 
unconverted in urine and has a long half-life of between 10 
to 13 h [103] Table 3. SK-0405 an even newer compound 
can inhibit DPP-4 for an even longer period, when compared 
to vildagliptin (1) [104]. Many other DPP-4 inhibitors, in-
cluding P93/01, NVP-DPP728, 815541A, GSK23A and 
valine-pyrrolidide (9) are still in the experimental phase, and 
little is known therefore about their mechanism of action or 
possible side effects (Table 3). 
  Neutral endopeptidase (NEP), a membrane-bound met-
allo-endopeptidase, which can degrade amyloid beta has also 
been shown to be capable of degrading small peptides, in-
cluding GLP-1 [105]. In fact it has been shown that NEP-
24.11 can degrade as much as 50% of GLP-1 in circulation. 
Therefore, the inhibition of both DPP-4 and NEP-24.11 
would be superior to the inhibition of DPP-4 alone in the 
maintenance of optimal therapeutic level of GLP-1 [106].  
Advantages, Disadvantages and Limitations of Incretins 
and DPP-4 Inhibitors 
  Like any other group of drug, incretins and DPP-4 inhibi-
tors have their pros and cons. The positive side of incretins is 
their ability to stimulate secretion in a glucose-dependent 
manner thereby reducing the possibility of sudden hypogly-
caemia. Satiety and weight loss can also be achieved during 
treatment with incretins [107-109]. The chance of compli-
ance is high in patients taking incretin/incretin mimetics be-
cause they can be dispensed once a day or even once in 
week. The down side of increting and its analogue is that 
they can only be given by injection [110], which comes 
along with fear of injecting oneself and infection at sites of 
administration. In addition, some classes of incretin analogue 
(liraglutide) have been shown to cause thyroid C-cell neo-
plasm, at least in rodent models (Tables 4 and 5a-b). 
CONCLUSION 
  The pathology and course of T2DM involves a progres-
sive malfunction of pancreatic beta cell due in part to insuf-
ficient mass. The incretins including GIP and GLP-1 play a 
role in the regulation of glucose metabolism via meal-
stimulated insulin release. Even though diabetic patients may 
display a lower sensitivity to GIP, their reactions to GLP-1 
are largely conserved. Therefore, the maintenance of an op-
timal GLP-1 level would be a logical strategy for the treat-
ment of patients with T2DM. Optimal GLP-1 level can be 
achieved by the use of long-acting GLP-1 receptor agonists 
Table 3.  Chemical Structures of Newer DPP-4 Inhibitors 
# Compound's 
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Chemical Structure 
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Table 4.  Advantages, Disadvantages and Limitations of GLP-1, Agonists and its Analogues 
  Advantages Disadvantages  Limitations 
 
 
GLP-1 
•  Reduction of body weight by about 1.9% (in 
T2DM patients [107] 
•  Enhanced sense of fullness  [108] 
•  Increase insulin secretion [109] 
• Gastrointestinal side effects 
[110] 
• Expensive [110] 
 
Can only be given subcutaneously 
[110] 
 
Liraglutide  
(a GLP-1 ana-
logue) 
 
•  Action depends on glucose level 
•  Increases satiety 
•  Enhance regeneration of new beta cells 
•  Decreases plasma lipid level  
•  Long half life 
[37], [38] 
• Gastrointestinal side-effects  •  Can only be given subcutaneously 
•  Thyroid C-cell cancer risk [111] 
•   Cancer risk disputed in human 
[112]  
Albiglutide 
(a GLP-1 ana-
logue) 
•  Very long half life (4-7 days) 
•  DPP-4 resistant 
•  Reduce fasting blood glucose [47, 48] 
• Skin rash at site of injection 
 
[47, 48] 
Can only be given subcutaneously 
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or alternatively by DPP-4 inhibitors in order to prevent deg-
radation of incretins. GLP-1 can reduce postprandial hyper-
glycemia, delay the outflow of food from the stomach, re-
duce appetite, body weight and preserve pancreatic beta cell 
mass.  
  Since DPP are ubiquitous and are involved in the sup-
pression of tumour cells, subclasses of DPP-4 inhibitors that 
are more selective for enzymes that degrade incretins that 
will cause less adverse effect are the future drugs in this 
class. 
Table 5a.  Advantages, Disadvantages and Limitations of Newer DPP-4 Inhibitors 
 Advantages  Disadvantages  Limitations 
 
Vildagliptin 
 
•  Can be used with metformin 
•  Oral administration 
      [81-89] 
•  coronary artery disease  
•  deep venous thrombosis  
•  acute uveitis  
•  renal calculus 
•  skin lesion [113] 
•  Risk of developing cancer 
[114]  
 
Sitagliptin 
•  Can be used with metformin 
•  Oral administration 
•  Lower occurrence of side effect [75-80] 
•  Pancreatitis  
•  Nausea 
         [115] 
•  Risk of developing cancer 
[114] 
Saxagliptin  •  Oral administration 
•  Once daily 
•  More effective when combined with 
other oral hypoglycemic agents [73-78] 
•  headache 
•  infections of upper respiratory & urinary  
tracts [116]  
•  Leukopenia?  
•  Metabolized by CYP 3A4 [117]  
•  Risk of developing cancer 
[114] 
•  Potential for drug interaction 
      [117] 
 
Table 5b.  Advantages, Disadvantages and Limitations of Newer DPP-4 Inhibitors 
 Advantages  Disadvantages  Limitations 
Denagliptin  •  Reduces HbA1C 
•  Lowers fasting blood glucose  
•  Oral administration 
•  Once daily [97] 
•  Nasopharyngitis 
•  Nausea 
•  Headache 
•  Upper respiratory 
       tract infection [118] 
•  Risk of developing cancer 
[114] 
Alogliptin  •  Highly selective inhibition of DPP-4 
•  Never  inactivate CYP 450 enzymes 
•  Used with exercise or diet 
•  Can be combined with oral hypoglycemic 
agents [98-99] 
•  Constipation 
•  Dizziness 
•  Headache  
[119]  
•  Risk of developing cancer 
[114] 
P32/98 (Isoleucyl 
thiazolidide) 
•  increase insulin secretion in rodent models 
•  improve glucose tolerance 
       [120]  
•  Severe toxic effects 
•  Not selective 
 
    [121]  
•  Risk of developing cancer 
[114] 
Linagliptin 
 (BI 1356) 
•  Oral administration 
•  Once daily 
•  More effective when combined with other 
oral hypoglycemic agents 
•  Long half life  
     [102, 122] 
•  Headache 
•  Upper respiratory infection 
•  Pharyngitis 
•  Muscle pain 
[122] 
•  Risk of developing cancer 
[114] 
Dutogliptin 
 PHX1149   
 
•  Oral administration 
•  Once daily 
•  More effective when combined with other 
oral hypoglycemic agents 
[103-104] 
•  Large dose (400 mg) required for opti-
mal reductions of abnormal parameters 
•  Risk of developing cancer 
[114] 
Valine-pyrrolidide  •  Increases insulin release [123] 
•  More potentiation of GIP levels [124] 
•  Inhibits DPP-8 as well  •  Risk of developing cancer 
[114] Role of Incretins and DPP-4 Inhibitors in Diabetes  The Open Medicinal Chemistry Journal, 2011, Vol. 5    89 
REFERENCES 
[1]  D’Souza, A.; Hussain, M.; Howarth, F.C.; Woods, N.M.; Bidasee, 
K.; Singh, J. Pathogenesis and pathophysiology of accelerated athe-
rosclerosis in the diabetic heart. Mol. Cell Biochem., 2009, 331, 89-
116. 
[2]  Kumar, P.J.; Clark, M. Diabetes mellitus and other disorders of 
metabolism. In: Kumar PJ, Clark M (eds) Textbook of Medicine. 
Saunders, London, 2006, 1069-1122. 
[3]  Havale, S.H.; Pal, M. Medicinal chemistry approaches to the inhi-
bition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. 
Bioorg. Med. Chem., 2009, 17, 1783-1802. 
[4]  Amos, A.; McCarty, D.; Zimmet, P. The rising global burden of 
diabetes and its complications: estimates and projections to the year 
2010. Diabet. Med., 1997, 14, S1-S85. 
[5]  Zimmet, P.Z.; Alberti, K.G. Globalisation and the noncommunica-
ble disease epidemic. Obesity, 2006, 14, 1-3. 
[6]  World Health Organization: Definition, Diagnosis and Classifica-
tion of Diabetes Mellitus and its Complications; Part 1. Diagnosis 
and Classification of Diabetes Mellitus. Geneva: Department of 
Non-communicable Disease Surveillance, WHO; 1999. 
[7]  King, H.; Aubert, R.; Herman, W. Global burden of diabetes, 1995-
2025. Prevalence, numerical estimates and projections. Diabetes 
Care, 1998, 21, 1414-1431. 
[8]  Butler, A.E.; Janson, J.; Bonner-Weir, S.; Ritzel, R.; Rizza, R.A.; 
Butler, P.C. Beta-cell deficit and increased beta-cell apoptosis in 
humans with type 2 diabetes. Diabetes, 2003, 51, 102-10. 
[9]  Karaca, M.; Magnan, C.; Kargar, C. Functional pancreatic beta-cell 
mass: Involvement in type 2 diabetes and therapeutic intervention. 
Diabetes Metab., 2009, 35, 77-84. 
[10]  McIntyre, N.; Holdsworth, C.D.; Turner, D.S. New interpretation 
of oral glucose tolerance. Lancet, 1964, 2, 20-21. 
[11]  Labarre, J. Sur les possibilities d’un traitement due diabete parl 
’incretine. Bull. Acad. R. Med. Belg. 1932, 12, 620-634. 
[12]  Creutzfeldt, W.; Ebert, R. New developments in the incretin con-
cept. Diabetologia, 1985, 28, 565-573. 
[13]  Pederson, R.A.; Brown, J.C. The insulinotropic action of gastric 
inhibitory polypeptide in the perfused isolated rat pancreas. Endo-
crinology, 1976, 99, 780-785. 
[14]  Ross, S.A.; Dupre, J. Effects of ingestion of triglyceride or galac-
tose on secretion of gastric inhibitory polypeptide and on responses 
to intravenous glucose in normal and diabetic subjects. Diabetes, 
1978, 27, 327-333. 
[15]  Kieffer, T.J.; Habener, J.F. The glucagon-like peptides. Endocr. 
Rev., 1999, 20, 876-913. 
[16]  Wideman, R.D.; Kieffer, T.J. Glucose-dependent insulinotropic 
polypeptide as a regulator of beta cell function and fate. Horm. Me-
tab. Res., 2004, 36, 782-786. 
[17]  Nikolaidis, L.A.; Elahi, D.; Shen, Y.; Shannon, R.P. Active me-
tabolite of GLP-1 mediates myocardial glucose uptake and im-
proves left ventricular performance in conscious dogs with dilated 
cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, 
H2401-H2408. 
[18]  Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; 
Husain, M. Cardioprotective and vasodilatory actions of glucagon-
like peptide 1 receptor are mediated through both glucagon-like 
peptide 1 receptor-dependent and –independent pathways. Circula-
tion, 2008, 117, 2340-2350. 
[19]  Sokos, G.G.; Bolukoglu, H,; German, J.; Hentosz, T.; Magovern, 
G.J.; Maher, T.D.; Dean, D.A.; Bailey, S.H.; Marrone, G.; 
Benckart, D.H.; Elahi, D.; Shannon, R.P. Effect of glucagon-like 
peptide-1 (GLP-1) on glycemic control and left ventricular function 
in patients undergoing coronary artery bypass grafting. Am. J. Car-
diol. 2007, 100, 824-829. 
[20]  Sonne, D.P.; Engstrom, T.; Treiman, M. Protective effects of GLP-
1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-
reperfusion injury in rat heart. Regul. Pept., 2008, 146, 243-249. 
[21]  Ding, K.H.; Zhong,  Q.; Xie,  D.; Chen,  H.X.; Della-Fera,  M.A.; 
Bollag,  R.J.; Bollag,  W.B.; Gujral,  R.; Kang,  B.; Sridhar,  S.; 
Baile, C.; Curl, W.; Isales, C.M. Impact of glucose-dependent insu-
linotropic peptide on age-induced bone loss. J. Bone Miner. Res., 
2008, 23, 536-543. 
[22]  Xie, D.; Zhong, Q.; Ding, K.H.; Cheng, H.; Williams, S.; Correa, 
D.; Bollag, W.B.; Bollag, R.J.; Insogna, K.; Troiano, N.; Coady, 
C.; Hamrick, M.; Isales, C.M. Glucose-dependent insulinotropic 
peptide-overexpressing transgenic mice have increased bone mass. 
Bone, 2007, 40, 1352-1360. 
[23]  Meier, J.J.; Gallwitz, B.; Siepmann, N.; Holst, J.J.; Deacon, C.F.; 
Schmidt, W.E.; Nauck, M.A. Gastric inhibitory polypeptide (GIP) 
dosedependently stimulates glucagon secretion in healthy human 
subjects at euglycaemia. Diabetologia, 2003, 46, 798-801. 
[24]  Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. 
Gastroenterology, 2007, 132, 2131-2157. 
[25]  Gautier, J.F.; Choukem, S.P.; Girard, J. Physiology of incretins 
(GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes 
Metab., 2008, 34 (Suppl 2), S65-S72. 
[26]  Hansen, L.; Deacon, C.F.; Orskov, C.; Holst, J.J. Glucagon-like 
peptide-1-(7–36) amide is transformed to glucagon-like peptide-1-
(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying 
the L cells of the porcine intestine. Endocrinology,  1999,  140, 
5356-5363. 
[27]  Deacon, C.F.; Johnsen, A.H.; Holst, J.J. Degradation of glucagon-
like peptide-1 by human plasma in vitro yields an N-terminally 
truncated peptide that is a major endogenous metabolite in vivo. J. 
Clin. Endocrinol. Metab., 1995, 80, 952-957. 
[28]  Mentlein, R. Dipeptidyl-peptidase IV (CD26) - role in the inactiva-
tion of regulatory peptides. Regul. Pept., 1999, 85, 9-24. 
[29]  Green, B.D.; Flatt, P.R. Incretin hormone mimetics and analogues 
in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab., 
2007, 21, 497-516. 
[30]  Eng, J.; Kleinman, W.A.; Singh, L.; Singh, G.; Raufman, J.P. Isola-
tion and characterization of exendin-4, an exendin-3 analogue, 
from Heloderma suspectum venom. Further evidence for an ex-
endin receptor on dispersed acini from guinea pig pancreas. J. Biol. 
Chem., 1992, 267, 7402-7405. 
[31]  Barnett, A. Exenatide. Expert Opin. Pharmacother., 2007, 8, 2593-
2608. 
[32]  Xu, G.; Stoffers, D.A.; Habener, J.F.; Bonner-Weir, S. Exendin-4 
stimulates both beta-cell replication and neogenesis, resulting in in-
creased beta-cell mass and improved glucose tolerance in diabetic 
rats. Diabetes, 1999, 48, 2270-2276. 
[33]  Tourrel, C.; Bailbe, D.; Meile, M.J.; Kergoat, M.; Portha, B. Glu-
cagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis 
in streptozotocin-treated newborn rats resulting in persistently im-
proved glucose homeostasis at adult age. Diabetes, 2001, 50, 1562-
1570. 
[34]  Tourrel, C.; Bailbe, D.; Lacorne, M.; Meile, M.J.; Kergoat, M.; 
Portha, B. Persistent improvement of type 2 diabetes in the Goto–
Kakizaki rat model by expansion of the beta-cell mass during the 
prediabetic period with glucagon-like peptide-1 or exendin-4. Dia-
betes, 2002, 51, 1443-1452. 
[35]  Stoffers, D. A.; Desai, B.M.; DeLeon, D.D.; Simmons, R.A. Neo-
natal exendin-4 prevents the development of diabetes in the intrau-
terine growth retarded rat. Diabetes, 2003, 52, 734-740. 
[36]  Gedulin, B.R.; Nikoulina, S.E.; Smith, P.A.; Gedulin, G.; Nielsen, 
L.L.; Baron, A.D.; Parkes, D.G.; Young, A. Exenatide (exendin-4) 
improves insulin sensitivity and {beta}-cell mass in insulin-
resistant obese fa/fa Zucker rats independent of glycemia and body 
weight. Endocrinology, 2005, 146, 2069-2076. 
[37]  Degn, K.B.; Juhl, C.B.; Sturis, J.; Jakobsen, G.; Brock, B.; 
Chandramouli, V.; Rungby, J,; Landau, B.R.; Schmitz, O. One 
week's treatment with the long-acting glucagon-like peptide 1 de-
rivative liraglutide (NN2211) markedly improves 24-h glycemia 
and alpha- and beta-cell function and reduces endogenous glucose 
release in patients with type 2 diabetes. Diabetes, 2004, 53, 1187-
1194. 
[38]  Juhl, C.B.; Hollingdal, M.; Sturis, J.; Jakobsen, G.; Agerso, H.; 
Veldhuis, J.; Porksen, N.; Schmitz, O. Bedtime administration of 
NN2211, a long-acting GLP-1 derivative, substantially reduces 
fasting and postprandial glycemia in type 2 diabetes. Diabetes, 
2002, 51, 424-429. 
[39]  Sturis, J.; Gotfredsen, C.F.; Romer, J.; Rolin, B.; Ribel, U.; Brand, 
C.L.; Wilken, M.; Wassermann, K.; Deacon, C.F.; Carr, R.D.; 
Knudsen, L.B. GLP-1 derivative liraglutide in rats with beta-cell 
deficiencies: influence of metabolic state on beta-cell mass dynam-
ics. Br. J. Pharmacol., 2003, 140, 123-132. 
[40]  Bregenholt, S.; Moldrup, A.; Blume, N.; Karlsen, A.E.; Nissen, 
F.B.; Tornhave, D.; Knudsen, L.B.; Petersen, J.S. The long-acting 
glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell 90    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Lotfy et al. 
apoptosis in vitro. Biochem. Biophys. Res. Commun., 2005, 330, 
577-584. 
[41]  Wajchenberg, B.L. Beta-cell failure in diabetes and preservation by 
clinical treatment. Endocr. Rev., 2007, 28, 187-218. 
[42]  Tracy, M.A.; Ward, K.L.; Firouzabadian, L.; Wang, Y.; Dong, N.; 
Qian, R.; Zhang, Y. Factors affecting the degradation rate of 
poly(lactide-co-glycolide) microspheres in vivo and in vitro. Bio-
materials, 1999, 20, 1057-1062. 
[43]  Drucker, D.J.; Buse, J.B.; Taylor, K.; Kendall, D.M.; Trautmann, 
M.; Zhuang, D.; Porter, L. Exenatide once weekly versus twice 
daily for the treatment of type 2 diabetes: a randomised, open-label, 
non-inferiority study. Lancet, 2008, 372, 1240-1250. 
[44]  Kim, D.; MacConell, L.; Zhuang, D.; Kothare, P.A.; Trautmann, 
M.; Fineman, M.; Taylor K. Effects of once-weekly dosing of a 
long-acting release formulation of exenatide on glucose control and 
body weight in subjects with type 2 diabetes. Diabetes Care, 2007, 
30, 1487-1493. 
[45]  Nauck, M.A.; Ratner, R.E.; Kapitza, C.; Berria, R.; Boldrin, M.; 
Balena, R. Treatment with the human once-weekly glucagon-like 
peptide-1 analog taspoglutide in combination with metformin im-
proves glycemic control and lowers body weight in patients with 
type 2 diabetes inadequately controlled with metformin alone. Dia-
betes Care, 2009, 32, 1237-1243. 
[46]  Tomkin, G.H. Albiglutide, an albumin-based fusion of glucagon-
like peptide 1 for the potential treatment of type 2 diabetes. Curr. 
Opin. Mol. Ther., 2009, 11, 579-588. 
[47]  Matthews, J.E.; Stewart, M.W.; De Boever, E.H.; Dobbins, R.L.; 
Hodge, R.J.; Walker, S.E.; Holland, M.C.; Bush, M.A. Pharma-
codynamics, pharmacokinetics, safety, and tolerability of albiglu-
tide, a long-acting glucagon-like peptide-1 mimetic, in patients 
with type 2 diabetes. J. Clin. Endocrinol. Metab., 2008, 93, 4810-
4817. 
[48]  Bush, M.A.; Matthews, J.E.; De Boever, E.H.; Dobbins, R.L.; 
Hodge, R.J.; Walker, S.E.; Holland, M.C.; Gutierrez, M.; Stewart, 
M.W. Safety, tolerability, pharmacodynamics and pharmacokinet-
ics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in 
healthy subjects. Diabetes Obes. Metab., 2009, 11, 498-505. 
[49]  Baggio, L.L.; Huang, Q.L.; Brown, T.J.; Drucker, D.J. A recombi-
nant human glucagon-like peptide (GLP)-1-albumin protein (al-
bugon) mimics peptidergic activation of GLP-1 receptor-dependent 
pathways coupled with satiety, gastrointestinal motility, and glu-
cose homeostasis. Diabetes, 2004, 53, 2492-2500. 
[50]  Liu, M.J.; Shin, S.; Li, N.; Shigihara, T.; Lee, Y.S.; Yoon, J.W.; 
Jun, H.S. Prolonged remission of diabetes by regeneration of beta 
cells in diabetic mice treated with recombinant adenoviral vector 
expressing glucagon-like peptide-1. Mol. Ther., 2007, 15, 86-93. 
[51]  Kumar, M.; Hunag, Y.; Glinka, Y.; Prud'Homme, G.J.; Wang, Q. 
Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion con-
struct normalizes glucose levels in db/db mice. Gene Ther., 2007, 
14, 162-172. 
[52]  Deacon, C.F.; Nauck, M.A.; Meier, J.; Hücking, K.; Holst, J.J. 
Degradation of endogenous and exogenous gastric inhibitory poly-
peptide in healthy and in type 2 diabetic subjects as revealed using 
a new assay for the intact peptide. J. Clin. Endocrinol. Metab., 
2000, 85, 3575-3581. 
[53]  Deacon, C.F. Circulation and degradation of GIP and GLP-1. Hor-
mone Metab. Res., 2004, 36, 761-765. 
[54]  Lambeir, A.M.; Durinx, C.; Scharpe, S.; and De Meester, I. Dipep-
tidylpeptidase IV from bench to bedside: an update on structural 
properties, functions, and clinical aspects of the enzyme DPPIV. 
Crit. Rev. Clin. Lab. Sci., 2003, 40, 209-294. 
[55]  Abbott, C.A.; Baker, E.; Sutherland, G.R.; Mc Caughan, G.W. 
Genomic organization, exact localization, and tissue expression of 
the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics., 
1994, 40, 331-338. 
[56]  Pratley, R.E.; Gilbert, M. Targeting incretins in type 2 diabetes: 
Role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev. Diabet. 
Stud., 2008, 5, 73-94. 
[57]  Pratley, R.E. Overview of glucagon-like peptide-1 analogs and 
dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J. 
Med.; 2008, 10, 171. 
[58]  Ahren, B.; Landin-Olsson, M.; Jansson, P.A.; Svensson, M.; 
Holmes, D. Schweizer, A. Inhibition of dipeptidyl peptidase-4 re-
duces glycemia, sustains insulin levels and reduces glucagon levels 
in type 2 diabetes. J. Clin. Endocrino. Metab.,  2004,  89, 2078-
2084. 
[59]  Mari, A.; Sallas, W.M.; He, Y.L.; Watson, C.; Ligueros-Saylan, 
M.; Dunning, B.E.; Deacon, C.F.; Holst, J.J.; Foley, J.E. Vilda-
gliptin, a dipeptidyl peptidase-IV inhibitor, improves model-
assessed beta-cell function in patients with type 2 diabetes. J. Clin. 
Endocrino. Metab., 2005, 90, 4888-4894. 
[60]  Ahren, B.; Pacini, G.; Foley, J.E.; Schweizer, A. Improved meal-
related beta-cell function and insulin sensitivity by the dipeptidyl 
peptidase-IV inhibitor vildagliptin in metformin-treated patients 
with type 2 diabetes over 1 year. Diabetes Care, 2005, 28, 1936-
1940. 
[61]  Raz, I.; Hanefeld, M.; Xu, L.; Caria, C.; Williams-Herman, D.; 
Khatami, H. Efficacy and safety of the dipeptidyl peptidase-4 in-
hibitor sitagliptin as monotherapy in patients with type 2 diabetes 
mellitus. Diabetologia, 2006, 49, 2564-2571. 
[62]  Ahren, B.; Pacini, G.; Tura, A.; Foley,  J.E.; Schweizer,  A. Im-
proved meal-related insulin processing contributes to the enhance-
ment of B-cell function by the DPP-4 inhibitor vildagliptin in pa-
tients with type 2 diabetes. Hormone Metab. Res., 2007, 39, 826-
829. 
[63]  Ahren, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Tor-
geirsson, H.; Jansson, P.A.; Sandqvist, M.; Båvenholm, P.; Efendic, 
S.; Eriksson, J.W.; Dickinson, S.; Holmes, D. Inhibition of dipepti-
dyl peptidase IV improves metabolic control over a 4 week study 
period in type 2 diabetes. Diabetes Care, 2002, 25, 869-875. 
[64]  Brazg, R.; Xu, L.; Dalla Man, C.; Cobelli, C.; Thomas, K.; Stein, 
P.P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, 
to metformin on 24-h glycaemic control and beta-cell function in 
patients with type 2 diabetes. Diabetes Obes. Metab., 2007, 9, 186-
193. 
[65]  Ahren, B. Clinical results of treating type 2 diabetic patients with 
sitagliptin, vildagliptin or saxagliptin – diabetes control and poten-
tial dverse events. Best Pract. Res. Clin. Endocrinol. Metab., 2009, 
23, 487-498. 
[66]  Ahren, B. DPP-4 inhibitors. Best Pract. Res. Clin. Endocrinol. 
Metab., 2007, 21, 517-533. 
[67]  Ahren, B. Dipeptidyl peptidase-4 inhibitors: clinical data and clini-
cal implications. Diabetes Care, 2007, 30, 1344–1350. 
[68]  Karasik, A.; Aschner, P.; Katzeff, H.; Davies, M.J.;  Stein, P.P. 
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 
2 diabetes: a review of recent clinical trials. Curr. Med. Res. Opin-
ion, 2008, 24, 489-496. 
[69]  Ahren, B. Vildagliptin: novel pharmacological approach to treat 
type 2 diabetes. Therapy, 2008, 5, 79-90. 
[70]  Augeri, D.J.; Robl, J.A.; Betebenner, D.A. Magnin, D.R.; Khanna, 
A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, 
Q.; Han, S.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; 
Welzel, G.E.; Egan, D.M.; Marcinkeviciene, J.; Chang, S.Y.; 
Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann L.G. Discovery 
and preclinical profile of saxagliptin (BMS-477118): a highly po-
tent longacting, orally active dipeptidyl peptidase IV inhibitor for 
the treatment of type 2 diabetes. J. Med. Chem., 2006, 48, 5025-
5037. 
[71]  Bergman, A.J.; Cote, J.; Yi, B.; Marbury, T.; Swan, S.K.; Gottesdi-
ener, K.; Wagner, J.; Herman, G.A. Effect of renal insufficiency on 
the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibi-
tor. Diabetes Care, 2007, 30, 1862-1864. 
[72]  Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M.H.; He, 
H.; Hickey, G.J.; Kowalchick, J.E.; Leiting, B.; Lyons, K.; Mar-
silio, F.; McCann, M.E.; Patel, R.A.; Petrov, A.; Scapin, G.; Patel, 
S.B.; Roy, R.S.; Wu, J.K.; Wyvratt, M.J.; Zhang, B.B.; Zhu, L.; 
Thornberry, N.A.; Weber, A.E. (2R)-4-oxo-4-[3-(trifluoromethyl)-
5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-
trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl 
peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. 
Chem., 2005, 48, 141-151. 
[73]  Aschner, P.; Kipnes, M.S.; Lunceford, J.K.; Sanchez, M.; Mickel, 
C.; Williams-Herman, D.E. Effect of the dipeptidyl peptidase-4 in-
hibitor sitagliptin as monotherapy on glycemic control in patients 
with type 2 diabetes. Diabetes Care, 2006, 29, 2632-2637. 
[74]  Charbonnel, B.; Karasik, A.; Liu, J.; Wu, M.; Meininger, G. Effi-
cacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin 
added to ongoing metformin therapy in patients with type 2 diabe-Role of Incretins and DPP-4 Inhibitors in Diabetes  The Open Medicinal Chemistry Journal, 2011, Vol. 5    91 
tes inadequately controlled with metformin alone. Diabetes Care, 
2006, 29, 2638-2643. 
[75]  Karasik, A.; Charbonnell, B.; Liu, J.; Wu, M.; Meehan, A.; Mein-
inger, G. Sitagliptin added to ongoing metformin therapy enhanced 
glycemic control and beta-cell function in patients with type 2 dia-
betes. Diabetes, 2006, 55(suppl 1), 119-120 (Abstr 501-P). 
[76]  Rosenstock, J.; Brazg, R.; Andryuk, P.J.; McCrary S.C.; Lu, K.; 
Stein, P. Addition of sitagliptin to pioglitazone improved glycemic 
control with neutral weight effect over 24 weeks in inadequately 
controlled type 2 diabetes (T2DM). Diabetes, 2006, 55 (Suppl 1), 
132-133 (Abstr 556-P). 
[77]  Xu, L.; Williams-Herman, D.E. Initial combination therapy with 
sitagliptin, a selective DPP-4 inhibitor, and metformin leads to 
marked improvement in  cell function in patients with type 2 dia-
betes. Diabetologia, 2007, 50, (Suppl.) Abstract # 884. 
[78]  Migoya, E.M.; Miller, J.; Larson, P.; Tanes, M.; Hilliard, D.; Dea-
con, C.; Guitierrez, M.; Stoch, A.; Herman, G.A.; Stein, P.P.; 
Holst, J.J.; Wagner, J.A. Sitagliptin, a selective DPP-4 inhibitor, 
and metformin have complementary effects to increase active GLP-
1 concentrations. Diabetes, 2007, 56, A74 (Abstract). 
[79]  Herman, G.A.; Bergman, A.; Stevens, C.; Kotey, P.; Yi, B.; Zhao, 
P.; Dietrich, B.; Golor, G.; Schrodter, A.; Lasseter, K.C.; Kipnes, 
M.S.; Snyder, K.; Hilliard, D.; Tanen, M.; Cilissen, C.; De Smet, 
M.; De Lepeleire, I.; Van Dyck, K.; Wang, A.Q.; Zeng, W.; Da-
vies, M.J.; Tanaka, W.; Holst, J.J.; Deacon, C.F.; Gottesdiener, 
K.M.; Wagner, J.A. Effect of single oral doses of sitagliptin, a 
dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose 
levels after an oral glucose tolerance test in patients with type 2 
diabetes. J. Clin. Endocrinol. Metab., 2006, 91, 4612-4619. 
[80]  Mu, J.; Woods, J.; Zhou, Y.P.; Roy, R.S.; Li, Z.; Zycband, E.; 
Feng, Y.; Zhu, L.; Li, C.; Howard, A.D.; Moller, D.E.; Thornberry, 
N.A.; Zhang, B.B. Chronic inhibition of dipeptidyl peptidase-4 
with a sitagliptin analog preserves pancreatic beta-cell mass and 
function in a rodent model of type 2 diabetes. Diabetes, 2006, 55, 
1695-1704. 
[81]  Villhauer, E.B.; Brinkman, J.A.; Naderi, G.B.; Burkey, B.F.; Dun-
ning, B.E.; Prasad, K.; Mangold, B.L.; Russell, M.E.; Hughes, T.E. 
1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-
pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl 
peptidase IV inhibitor with antihyperglycemic properties. J. Med. 
Chem., 2003, 46, 2774-2789. 
[82]  El-Ouaghlidi, A.; Rehring, E.; Schweizer, A.; Holmes, D.; Nauck, 
M.A. The dipeptidyl peptidase IV inhibitor LAF237 does not ac-
centuate reactive hypoglyaemia caused by the sulfonylurea gliben-
clamide administered before an oral glucose load in healthy sub-
jects. Diabetes, 2003, 52 (Suppl 1), 118 (Abstr 507-P). 
[83]  Rosenstock, J.; Baron, M.A.; Camisasca, R.P.; Cressier, F.; Coutu-
rier, A.; Dejager, S. Efficacy and tolerability of initial combination 
therapy with vildagliptin and pioglitazone compared with compo-
nent monotherapy in patients with type 2 diabetes. Diabetes Obes. 
Metab., 2007, 9, 175-185. 
[84]  Garber, A.; Camisasca, R.P.; Ehrsam, E.; Collober-Maugeais, C.; 
Rochotte, E.; Lebeaut, A. Vildagliptin added to metformin im-
proves glycemic control and may mitigate metformin-induced GI 
side effects in patients with type 2 diabetes (T2DM). Diabetes, 
2006, 55(Suppl 1), 29 (Abstr 121-OR). 
[85]  Pratley, R.E.; Jauffret-Kamel, S.; Galbreath, E.; Holmes, D. 
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin 
improves glycemic control in subjects with type 2 diabetes. Horm. 
Metab. Res., 2006, 38, 423-428. 
[86]  Rosenstock, J.; Baron, M.A.; Schweizer, A.; Mills, D.; Dejager, S. 
Vildagliptin is as effective as rosiglitazone in lowering HbA1c but 
withoutweight gain in drugnaive patients with type 2 diabetes 
(T2DM). Diabetes, 2006, 55(Suppl 1), 133 (Abstr 557-P). 
[87]  Balas, B.; Baig, M.R.; Watson, C.; Dunning, B.E.; Ligueros-
Saylan, M.; Wang, Y.; He, Y.L.; Darland, C.; Holst, J.J.; Deacon, 
C.F.; Cusi, K.; Mari, A.; Foley, J.E.; DeFronzo, R.A. The dipepti-
dyl peptidase IV inhibitor vildagliptin suppresses endogenous glu-
cose production and enhances islet function after single dose ad-
ministration in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 
2007, 92, 12249-12255. 
[88]  Ahren, B.; Landin-Olsson, M.; Jansson, P.A.; Svensson, M.; 
Holmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 re-
duces glycemia, sustains insulin levels, and reduces glucagon levels 
in type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89, 2078-
2084. 
[89]  Azuma, K.; Rádiková1, Z.; Mancino, J.; Toledo, F.G.S.; Thomas, 
E.; Kangani, C.; Man, C.D.; Cobelli, C.; Holst, J.J.; Deacon, C.F.; 
He, Y.L.; Ligueros-Saylan, M.; Serra, D.; Foley J.E.; Kelley, D.E. 
Measurements of islet function and glucose metabolism with the 
DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. J. 
Clin. Endocrinol. Metab., 2008, 93, 459-464. 
[90]  D’Alessio, D.A.; Tso, P. GLP-1 reduces intestinal lymph flow, 
triglyceride absorption and lipoprotein production in rats. Am. J. 
Physiol., 2005, 288, 6943-6949.  
[91]  Tahrani, A.A., Milan, K. Piya, M.K. and Barnett, A.H. Saxagliptin: 
a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. 
Adv. Ther., 2009, 26 (3): 249-262. 
[92]  Kirby, M.S.; Dorso, C.; Wang, A.; Weigelt, C.; Kopcho, L.; Ha-
mann, L.; Marcinkeviciene, J. In vitro enzymologic characteristics 
of saxagliptin, a highly potent and selective DPP4 inhibitor with 
“slow binding” characteristics. Clin. Chem. Lab. Med., 2008, 46, 
A29. 
[93]  Rosenstock, J.; Sankoh, S.; List, J.F. Glucose-lowering activity of 
the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve pa-
tients with type 2 diabetes. Diabetes Obes. Metab., 2008, 10, 376-
386. 
[94]  Pratley, R.E.; Rosenstock, J.; Pi-Sunyer, F.X.; Banerji, M.A.; 
Schweizer, A.; Couturier, A.; Dejager, S. Management of type 2 
diabetes in treatment-naive elderly patients: benefits and risks of 
vildagliptin monotherapy. Diabetes Care, 2007, 30, 3017–3022. 
[95]  Rosenstock, J.; List, J.; Sankoh, S.; Chen, R. Efficacy and tolerabil-
ity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve 
subjects with type 2 diabetes: results from a phase 2 dose-ranging 
study. Presented at: 43rd annual meeting of the European Society 
for the Study of Diabetes, 2007, September 17-21; Amsterdam, 
Netherlands. Abstract. 
[96]  Defronzo, R.A.; Hissa, M.; Blauwet, M.B.; Chen, R.S. Saxagliptin 
added to metformin improves glycemic control in patients with 
type 2 diabetes. Presented at: 67th Scientific Sessions of the 
American Diabetes Association; June 22-26, 2007; Chicago, IL. 
2007, Abstract 0285-OR. 
[97]  Demuth, H.U.; McIntosh, C.H.; Pederson, R.A. Type 2 diabetes—
therapy with dipeptidyl peptidase IV inhibitors, Biochim. Biophys 
Acta, 2005, 1751, 33-44.  
[98]  Lee, B.; Shi, L.; Kassel, D.B.; Asakawa, T.; Takeuchi, K.; Christo-
pher, R.J. Pharmacokinetic, pharmacodynamic, and efficacy pro-
files of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in 
rats, dogs, and monkeys. Eur. J. Pharmacol., 2008, 28, 306-314. 
[99]  Fleck, P.; Mekki, Q.; Kipnes, M.; Wilson, C.; Pratley, R. Efficacy 
and safety of alogliptin and glyburide combination therapy in pa-
tients with type 2 diabetes. Diabetologia, 2008, 51(Suppl.), S37. 
[100]  Pospisilik, J.A.; Martin, J.; Doty, T.; Ehses, J.A.; Pamir, N.; Lynn, 
F.C.; Piteau, S.; Demuth, H.U.; McIntosh, C.H.; Pederson, R.A. 
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell 
survival and islet neogenesis in streptozotocin induced diabetic 
rats. Diabetes, 2003, 52, 741-750. 
[101]  Thomas, L.; Himmelsbach, F.; Eckhardt, M.; Langkopf, E.; Mark, 
M. BI 1356, a novel and selective xanthine based DPP-IV inhibitor, 
exhibits a superior profile when compared to sitagliptin and vilda-
gliptin. Diabetologia, 2007, 50, (Suppl.) Abstract # 879. 
[102]  Dugi, K.A.; Heise, T.; Ring, A.; Graefe-Mody, U.; Ritzhaupt, A.; 
Huettner, S. BI 1356, a novel xanthine-based DPP-IV inhibitor, ex-
hibits high potency with a wide therapeutic window and signifi-
cantly reduces postprandial glucose excursions after an OGTT. 
Diabetologia, 2007, 50, (Suppl.) Abstract # 890. 
[103]  Guler, H.P. PHX1149, a selective DPP4 inhibitor, improves post-
prandial blood glucose control in patients with type 2 diabetes. 
Diabetologia, 2007, 50, (Suppl.) Abstract #114. 
[104]  Verspohl, E.J. Novel therapeutics for type 2 diabetes: Incretin 
hormone mimetics (glucagon-like peptide-1 receptor agonists) and 
dipeptidyl peptidase-4 inhibitors. Pharmacol. Therapeut.,  2009, 
124, 113-138. 
[105]  Pardossi-Piquard, R.; Dunys , J.; Yu, G.; St George-Hyslop, P.; 
Alves da Costa, C.; Checler, F. Neprilysin activity and expression 
are controlled by nicastrin. J. Neurochem., 2006, 97, 1052-1056. 
[106]  Plamboeck, A.; Holst, J.J.; Carr, R.D.; Deacon, C.F. Neutral en-
dopeptidase 24.11 and dipeptidyl peptidase IV are both mediators 92    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Lotfy et al. 
of the degradation of glucagon-like peptide 1 in the anaesthetised 
pig. Diabetologia, 2005, 48, 1882-1890.  
[107]  Zander, M.; Madsbad, S.; Holst, J.J. GLP-1 for six weeks reduces 
body weight and improves insulin sensitivity and glycemic control 
in patients with Type 2 diabetes. Diabetes 2001,  50 (Suppl. 2), 
A31. 
[108]  Gutzwiller, J-P., Drewe, J., Go¨ke, B., Schmidt, H., Rohrer, B., 
Lareida, J., Beglinger, C.,. Glucagon-like peptide-1 promotes sati-
ety and reduces food intake in patients with diabetes mellitus type 
2. Am. J. Physiol. 1999, 276, R1541-R1544 
[109]  Holst, J.J., Ørskov, C., Vagn-Nielsen, O., Schwartz, T.W. Trun-
cated glucagon-like peptide 1, an insulin-releasing hormone from 
the distal gut. FEBS Lett. 1987, 211, 169-174. 
[110]  Nyenwe, E.A.; Jerkins, T.W.; Umpierrez, G.E.; Kitabchi, A.E. 
Management of type 2 diabetes: evolving strategies for the treat-
ment of patients with type 2 diabetes. Metabolism 2011, 60, 1- 23 
[111]  Bjerre Knudsen, L.; Madsen, L.W.; Andersen, S.; Almholt, K.; de 
Boer, A.S.; Drucker, D.J.; Gotfredsen, C.; Egerod, F.L.; Hegelund, 
A.C.; Jacobsen, H.; Jacobsen, S.D.; Moses, A.C.; Mølck, A.M.; 
Nielsen, H.S.; Nowak, J.; Solberg, H.; Thi, T.D.; Zdravkovic, M. 
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid 
C-cells causing calcitonin release and C-cell proliferation. 
Endocrinology 2010, 151, 1473-1486.  
[112]  Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. 
GLP-1 and calcitonin concentration in humans: lack of evidence of 
calcitonin release from sequential screening in over 5000 subjects 
with type 2 diabetes or nondiabetic obese subjects treated with the 
human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011, 
96(3), 853-860. 
[113]  Bosi, E.; Camisasca, R.P.; Collober, C.; Rochotte, E.; Garber, A.J. 
Effects of vildagliptin on glucose control over 24 weeks in patients 
with type 2 diabetes inadequately controlled with metformin. Dia-
betes Care, 2007, 30, 890-895 
[114]  Wesley, U.V.; McGroarty, M.; Homoyouni, A. Dipeptidyl pepti-
dase inhibits malignant phenotype of prostate cancer cells by 
blocking basic fibroblast growth factor signaling pathway. Cancer 
Res, 2005, 65, 1325-34 
[115]  Olansky, L. Do incretin-based therapies cause acute pancreatitis? J 
Diabetes Sci Technol, 2010, 4, 228-229 
[116]  Neumiller, J.J.; Campbell, R.K. Saxagliptin: a dipeptidyl peptidase-
4 inhibitor for the treatment of type 2 diabetes mellitus. Am J 
Health Syst Pharm, 2010, 67, 1515-25. 
[117]  Anonymous. Saxagliptin. No more effective than other gliptins, but 
a high potential for drug interactions. Prescrire Int., 2011, 20, 33-
37. 
[118]  http://www.gsk-clinicalstudyregister.com/result_detail.jsp? proto-
colId = 100925&studyId=ED33C31C-01D3-4025-B568-910-
D2FADDA37 & compound=Denagliptin 
[119]  Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, 
Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tol-
erability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a 
randomized, double-blind, placebo-controlled, multiple-dose study 
in adult patients with type 2 diabetes. Clin Ther, 2008, 30, 499-512. 
[120]  Pederson, R.A.; White, H.A.; Schlenzig, D.; Pauly, R.P.; McIntosh, 
C.H.S.; Demuth, H.U. Improved Glucose Tolerance in Zucker 
Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV 
Inhibitor Isoleucine Thiazolidide. Diabetes 1998, 47, 1253-1258 
[121]  Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), 
a selective dipeptidyl peptidase IV inhibitor for the treatment of 
type 2 diabetes. Curr Top Med Chem., 2007, 7, 557-568. 
[122]  Forst, T.; Uhlig-Laske, B.; Ring, A.; Graefe-Mody, U.; Friedrich, 
C.; Herbach, K.; Woerle, H.-J; Dugi, K. A. Linagliptin (BI 1356), a 
potent and selective DPP-4 inhibitor, is safe and efficacious in 
combination with metformin in patients with inadequately con-
trolled Type 2 diabetes. Diabetic Medicine, 2010, 27, 1409-1419. 
[123]  Larsen MO, Rolin B, Ribel U, Wilken M, Deacon CF, Svendsen O, 
Gotfredsen CF, Carr RD. Valine pyrrolidide preserves intact glu-
cose-dependent insulinotropic peptide and improves abnormal glu-
cose tolerance in minipigs with reduced beta-cell mass. Exp Diabe-
sity Res., 2003, 4, 93-105. 
[124]  Ahrén B, Hughes TE. Inhibition of dipeptidyl peptidase-4 aug-
ments insulin secretion in response to exogenously administered 
glucagon-like peptide-1, glucose-dependent insulinotropic polypep-
tide, pituitary adenylate cyclase-activating polypeptide, and gastrin-
releasing peptide in mice. Endocrinology 2005, 146, 2055-2059.  
 
 
Received: February 12, 2011  Revised: March 27, 2011   Accepted: March 30, 2011 
 
© Lotfy et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 
 
 
 
 